hu14の高リスク神経芽細胞腫患者における安全性と有効性の研究 (SHINE)
高リスク神経芽腫患者を対象としたhu14.18K322Aを化学療法と併用した場合の有効性、安全性、忍容性を特徴づけ評価する第2相/第3相試験
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a Phase 2/3, open label, single arm study, evaluating how well hu14.18K322A works and how safe it is in combination with chemotherapy, in relapsed and refractory high-risk neuroblastoma (HRNB) patients.
The study is in 2 parts. The first part of the study will test two doses of hu14.18K322A to give with chemotherapy in 12 patients to confirm the best dose. Once the best dose is found, Part 2 of the study will recruit up to an additional 66 participants with relapsed disease and 66 participants with refractory disease.
Children and young people who take part in the study must be between 18 months and 18 years old at the time of consent and have confirmed HRNB that has spread to other parts of the body. It is expected that participants will receive up to 12 cycles of treatment. Once the treatment has finished, participants will be followed up to study long-term effects.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
San Francisco、California、アメリカ、94143
- 募集
- University of California San Francisco (UCSF)
-
コンタクト:
- Kieuhoa Vo, Dr
- 電話番号:(415) 476-3831
- メール:Kieuhoa.Vo@ucsf.edu
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Children's Hospital Colorado Anschutz Medical
-
コンタクト:
- Navin Pinto MD, MD
- 電話番号:720-777-8134
- メール:navin.pinto@childrenscolorado.org
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- The University of Chicago
-
コンタクト:
- Ami V Desai, Dr
- 電話番号:773-702-6808
- メール:adesai12@bsd.uchicago.edu
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55454
- 募集
- University of Minnesota Masonic Children's Hospital
-
コンタクト:
- Robin Williams, MD
- 電話番号:612-626-2778
- メール:will4877@umn.edu
-
-
New York
-
The Bronx、New York、アメリカ、10467
- 募集
- The Children's Hospital at Montefiore
-
コンタクト:
- Alice Lee, MD
- 電話番号:718-741-2342
- メール:alee5@montefiore.org
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27705
- 募集
- Duke University Medical Center
-
コンタクト:
- Jessica Sun, MD
- 電話番号:919-684-3401
- メール:jessica.sun@duke.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia
-
コンタクト:
- Rochelle Bagatell MD
- 電話番号:+1 (215) 590-2299
- メール:bagatellr@chop.edu
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- University of Texas Southwestern
-
コンタクト:
- Tanya C Watt
- 電話番号:6147955338
- メール:Tanya.Watt@utsouthwestern.edu
-
-
-
-
-
Newcastle upon Tyne、イギリス、NE1 4LP
- 募集
- Royal Victoria Infirmary
-
コンタクト:
- Quentin Campbell-Hewson, Dr
- 電話番号:0191 2821337
- メール:quentin.campbellhewson@nhs.net
-
Sutton、イギリス、SM2 5PT
- 募集
- Royal Marsden NHS Foundation Trust
-
コンタクト:
- Sucheta J Vaidya, Dr
- 電話番号:023 8120 6334
- メール:sucheta.vaidya@icr.ac.uk
-
-
Hampshire
-
Southampton、Hampshire、イギリス、SO16 6YD
- 募集
- Southampton Children's Hospital
-
コンタクト:
- Juliet Gray, Dr
- 電話番号:+44-(0)23 8120 5213
- メール:juliet.gray@uhs.nhs.uk
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1E8
- 募集
- The Hospital for Sick Children
-
コンタクト:
- Daniel Morgenstern, DR
- 電話番号:427565 416-813-7654
- メール:daniel.morgenstern@sickkids.ca
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- University Hospital Vall d'Hebron
-
コンタクト:
- Lucas Moreno Retortillo, Dr
- 電話番号:2887 934 89 30 00
- メール:lucas.moreno@vallhebron.cat
-
Barcelona、スペイン、08950
- 募集
- Hospital Sant Joan de Deu
-
コンタクト:
- Jaume Mora, Dr
- 電話番号:+34 93 600 97 33
- メール:jaume.mora@sjd.es
-
Madrid、スペイン、28009
- 募集
- Hospital Infantil Universitario Niño Jesús
-
コンタクト:
- Beatriz Vergara Munoz, Dr
- 電話番号:+34616531224
- メール:beatriz.vergara@salud.madrid.org
-
Valencia、スペイン、46026
- 募集
- Unidad De Oncohematologia Pediatrica
-
コンタクト:
- Adela canete, Dr
- 電話番号:686933743
- メール:canyete_ade@gva.es
-
-
-
-
-
Copenhagen、デンマーク、2100
- 募集
- Rigshospitalet
-
コンタクト:
- Karsten Nysom, Dr
- 電話番号:35 45 08 09
- メール:karsten.nysom@regionh.dk
-
-
-
-
-
Berlin、ドイツ、13353
- 募集
- Charité - Universitätsmedizin Berlin
-
コンタクト:
- Hedi Deubzer, Dr
- 電話番号:+49 30 450 566 715
- メール:hedwig.deubzer@charite.de
-
-
-
-
-
Marseille、フランス、13005
- 募集
- La Timone Children's Hospital
-
コンタクト:
- Gabriel Revon-Riviere, Dr
- 電話番号:04 91 38 68 22
- メール:gabriel.revon-riviere@ap-hm.fr
-
Paris、フランス、75005
- 募集
- Institut Curie
-
コンタクト:
- Amaury Leruste, Dr
- 電話番号:+33 (0)1 44 32 40 15
- メール:amaury.leruste@curie.fr
-
Villejuif、フランス、94800
- 募集
- Gustave Roussy
-
コンタクト:
- Pablo Berlanga, Dr
- 電話番号:(+33) 142 11 41 67
- メール:PABLO.BERLANGA@gustaveroussy.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
-
Are ≥18 months to <18 years of age at time of informed consent or assent.
-
Are initially diagnosed with histologically proven HRNB with metastatic disease.
-
Have evaluable or measurable disease per International Neuroblastoma Response Criteria (INRC)
-
Have a Lansky performance status of ≥50 (≤16 years ) or Karnofsky performance status ≥50% (for >16 years).
-
Have recovered from the toxic effects of prior chemotherapies
-
Are at least 2 weeks beyond any major tumor surgery
-
Meet the following organ function criteria, as measured within 1 week prior to Investigational Medicinal Product (IMP) dosing:
- BM function: i. Platelets ≥50 × 109/L ii. Absolute neutrophil count (ANC) ≥0.50 × 109/L
- Renal function: i. Age-adjusted serum creatinine ≤1.5 × upper limit of normal (ULN) for age. ii. Estimated glomerular filtration rate (eGFR) at least 60 mL/min using the Schwartz formula.
- Liver function: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3 × ULN and total bilirubin ≤1.5 × ULN.
- Cardiac function: i. Shortening fraction ≥27% or ejection fraction of ≥50% on echocardiogram. ii. Corrected QT Interval on electrocardiogram (ECG) using the Fridericia formula (QTcF) ≤ 480 msec.
- Lung function: i. Pulse oximetry considered normal in room air. No evidence of dyspnea at rest.
- Central nervous system (CNS) function: i. Participants with a history of CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.
-
If a fertile and sexually active woman of child-bearing potential (WOCBP), have a negative serum pregnancy test at Screening and then either a negative serum or urine test prior to each cycle and agree to use an acceptable and highly effective contraception method during the study and for at least 6 months after the last day of study treatment .
-
If a fertile and sexually active male, agree to use condoms during the study and for at least 6 months after the last dose of study treatment
-
If applicable based on age, are willing and able to provide voluntary written informed assent for participation in the study (as per local Institutional Review Board [IRB]/Independent Ethics Committee [IEC] requirements and if applicable based on regional age of consent) and to comply with all protocol requirements.
-
Their parent or legal guardian (if applicable based on regional age of consent) is willing and able to provide voluntary written informed consent for the participant's involvement in the study.
Exclusion Criteria
-
Any active uncontrolled infection at the time of enrollment. Any known history of infection with human immunodeficiency virus (HIV), or active or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Any contraindications to any of the study treatments.
-
Patients with >Grade 2 diarrhea.
-
Patients with disease of any major organ system that would compromise their ability to withstand chemoimmunotherapy.
-
Patients who have undergone a prior allogeneic stem cell transplant < 6 months ago or have undergone a solid organ transplant.
-
Patients who are on hemodialysis.
-
Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study except to manage allergic reactions
-
Patients on any other immunosuppressive medications
-
Patients who have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment.
-
Patients who have been diagnosed with any malignancy other than neuroblastoma.
-
Patients with symptoms of congestive heart failure.
-
Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required permanent discontinuation of the anti-GD2 therapy.
-
Patients participating in or planning to participate in another study that is either blinded or involves an IMP
-
If female, are breastfeeding, pregnant, or planning to become pregnant, or, if sexually active and of child-bearing potential, are unwilling to use an effective birth control method until 6 months after the last dose of study medication
-
Do not meet the following required washout periods prior to the administration of the first dose of hu14.18K322A:
- 14 days from prior systemic myelosuppressive chemotherapy.
- 7 days from prior systemic biologic antineoplastic agents (e.g. anti-cancer agents not known to be myelosuppressive - not associated with reduced platelet or ANC counts).
- 14 days from systemic steroids.
- ≥12 weeks from large field radiation therapy (i.e., total body irradiation, whole abdominal, total lung, ≥50% pelvis).
- 6 weeks from prior craniospinal radiotherapy or Iodine-131-metaiodobenzylguanidine (131I-MIBG) therapy.
- 2 weeks from radiotherapy to the primary tumor bed.
- ≥7 days from small treatment field radiation.
- 14 days or 5 half-lives (whichever is longer) from last administration of an IMP.
- >7 days prior to study enrollment for drugs that are strong inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4).
- ≥21 days and with recovery of all associated toxicities from receiving cellular therapy (e.g., modified T lymphocyte cells, Natural Killer (NK) cells, dendritic cells).
-
Ongoing need for any medication known or suspected to interfere with study treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の:より高用量
|
21-day cycle for a maximum of 12 cycles |
|
他の:低用量
|
21-day cycle for a maximum of 12 cycles |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR)
時間枠:Assessed at end of treatment (up to 12 months)
|
Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve a complete response (CR) or partial response (PR) according to the International Neuroblastoma Response Criteria (INRC) |
Assessed at end of treatment (up to 12 months)
|
|
Metastatic complete response rate (mCRR)
時間枠:Assessed at end of treatment (up to 12 months)
|
Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve an overall metastatic complete response (mCR) response |
Assessed at end of treatment (up to 12 months)
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
全生存期間 (OS)
時間枠:3年まで
|
3年まで
|
|
全体的転移性奏効率(mORR)
時間枠:治療終了時(最長12ヶ月)に評価
|
治療終了時(最長12ヶ月)に評価
|
|
response持続期間 (DOR)
時間枠:最初の奏効時から、疾患進行、研究中止、新たな治療開始、または死亡までの期間
|
最初の奏効時から、疾患進行、研究中止、新たな治療開始、または死亡までの期間
|
|
無増悪生存期間(PFS)
時間枠:サイクル1の開始から、進行が最初に認められるまで最長3年間追跡
|
サイクル1の開始から、進行が最初に認められるまで最長3年間追跡
|
|
イベントフリー生存期間(EFS)
時間枠:サイクル1の開始から、進行、二次性悪性腫瘍、またはあらゆる原因による死亡が最初に発生するまで、最長3年間追跡
|
サイクル1の開始から、進行、二次性悪性腫瘍、またはあらゆる原因による死亡が最初に発生するまで、最長3年間追跡
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- EPG-HU1418-201
- Health Canada (その他の識別子:302929)
- 169169 (その他の識別子:United States Food and Drug Administration (FDA or USFDA))
- 2025-524397-42-00 (その他の識別子:European Union Clinical Trials Regulation (EU CTR), European Medicines Agency (EMA))
- 1013435 (その他の識別子:Integrated Research Application System (IRAS), Medicines and Healthcare products Regulatory Agency (MHRA))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
At the current time there is no plan to share data. We have not received a research proposal that would require utilization of IPD. In the event we receive a request to access IPD a full evaluation will be undertaken and the data will be shared as appropriate and in compliance with the applicable regulations.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。